Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2017

View Archived Issues

AX-024 is a first-in-class inhibitor of TCR with activity in models of autoimmune diseases

Pfizer patents PDE4 inhibitors

Almirall discloses PI3K inhibitors

Lilly describes MetAP2 inhibitors

X4 initiates phase II/III trial of X4P-001 in patients with WHIM syndrome

Bayer Pharma reports development of anticancer agents

Australian scientists present KAT6A inhibitors

In vitro and in vivo data for the novel selective TYK2 inhibitor, NDI-031301

H3B-8800 demonstrates efficacy in spliceosome-mutant myeloid malignancies

Phase I results for INCB-039110 in acute graft-versus-host disease

University Hospital of Tubingen's therapy for CNGA3-linked achromatopsia designated E.U. orphan drug

European orphan drug designation for cabiralizumab for tenosynovial giant cell tumors

Abbott to close the acquisition of St. Jude Medical

Phase II study of trastuzumab emtansine in HER2-positive UBC or metastatic pancreas/cholangio cancer

Prima BioMed announces new LAG-3 agonist antibody

Phase III efficacy and safety study of EndoTAG-1 begins

Roche begins enrollment in phase I study of GDC-0077

Roche commences phase II trial of RO-7123520 in moderate to severely active rheumatoid arthritis

European orphan drug designation awarded to ivosidenib for AML

Tiziana Life Sciences in-licenses NI-1201 from Novimmune

Saniona reports topline data from phase IIa study of Tesomet in type 2 diabetes

Scancell announces final clinical study report on phase I/II trial of SCIB-1 in melanoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...